Andy Smith

Recent posts

Lax Approval Requirements Yield Blockbusters That Don’t Work
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
IBM Watson Health Data in Action – Epidemiology Studies
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson

Sponsored · Whitepaper
Doing Business in a World of Uncertainty
A growing nationalist and protectionist mindset around the world is creating a fresh set of challenges for global businesses
IDA Ireland

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!